Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 11/20 | 0.66 |
| ▸ | JAK1 | P23458 | 3/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.52 |
| ▸ | AKT2 | P31751 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7852410 | 0.91 | JAK3 (0.55) | JAK3JAK1LCKDOT1LAKT2 | |
| SCHEMBL28068350 | 0.84 | JAK3 (0.67) | JAK3JAK1LCKDOT1LAKT2 | |
| SCHEMBL28887147 | 0.84 | JAK3 (0.67) | JAK3JAK1LCKDOT1LAKT2 | |
| SCHEMBL6743217 | 0.84 | JAK3 (0.67) | JAK3JAK1LCKDOT1LAKT2 | |
| SCHEMBL3951466 | 0.83 | JAK3 (0.71) | JAK3JAK1LCKDOT1LAKT2 | |
| SCHEMBL2018758 | 0.81 | JAK3 (0.43) | JAK3JAK1JAK2SCN9AFFAR2 | |
| SCHEMBL2018756 | 0.81 | JAK3 (0.43) | JAK3JAK1JAK2SCN9AFFAR2 | |
| SCHEMBL3959625 | 0.81 | JAK3 (0.68) | JAK3JAK1LCKDOT1LAKT2 | |
| SCHEMBL29869816 | 0.81 | ROCK2 (0.65) | JAK3JAK1AKT2JAK2METAP2 | |
| SCHEMBL6742185 | 0.81 | JAK3 (0.67) | JAK3JAK1LCKDOT1LAKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569569-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1087971-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-6635762-B1 | Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants | PFIZER INC. | 2003-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | JAK3 2/4885JAK1 1/4885LCK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.